Regulus Historical Cash Flow

Stocks . USA . 
Stock . Regulus Therapeutics
RGLS Stock  USD 1.61  0.03  1.83%   
Analysis of Regulus Therapeutics cash flow over time is an excellent tool to project Regulus Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 215.7 K or Capital Expenditures of 611.5 K as it is a great indicator of Regulus Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
   Cash Flow   Balance Sheet   Income Statement
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Regulus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regulus Therapeutics is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

About Regulus Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Regulus balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Regulus's non-liquid assets can be easily converted into cash.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Regulus Therapeutics Cash Flow Chart

At this time, Regulus Therapeutics' Investments are comparatively stable compared to the past year. Cash Flows Other Operating is likely to gain to about 1.4 M in 2024, whereas Free Cash Flow is likely to drop (28.8 M) in 2024.
Stock Based Compensation  Begin Period Cash Flow  Capital Expenditures  End Period Cash Flow  
Add Fundamental

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Regulus Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Regulus Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from Regulus Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Regulus Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.At this time, Regulus Therapeutics' Investments are comparatively stable compared to the past year. Cash Flows Other Operating is likely to gain to about 1.4 M in 2024, whereas Free Cash Flow is likely to drop (28.8 M) in 2024.
 2023 2024 (projected)
Sale Purchase Of Stock17.2M27.7M
Change To Netincome1.9M1.8M

Regulus Therapeutics cash flow statement Correlations

Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Depreciation
Other Non Cash Items
Capital Expenditures
Net Income
End Period Cash Flow
Change To Liabilities
Change To Netincome
Sale Purchase Of Stock
Change To Inventory
Investments
Net Borrowings
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Change Receivables
Change To Operating Activities
Issuance Of Capital Stock
Change In Cash
-0.210.220.28-0.710.0-0.10.090.050.70.240.00.340.26-0.050.050.530.250.20.18-0.330.47
Stock Based Compensation
-0.21-0.82-0.22-0.010.650.690.12-0.85-0.310.040.84-0.43-0.770.560.32-0.5-0.72-0.25-0.160.1-0.29
Free Cash Flow
0.22-0.820.370.01-0.74-0.40.30.90.320.15-0.710.440.41-0.61-0.170.570.56-0.01-0.07-0.020.22
Change In Working Capital
0.28-0.220.37-0.3-0.17-0.350.41-0.040.10.56-0.260.070.360.040.310.430.540.460.46-0.05-0.02
Begin Period Cash Flow
-0.71-0.010.01-0.3-0.440.17-0.210.190.01-0.21-0.11-0.33-0.16-0.16-0.26-0.6-0.31-0.25-0.250.50.06
Depreciation
0.00.65-0.74-0.17-0.440.28-0.03-0.75-0.45-0.250.62-0.1-0.280.370.25-0.15-0.30.090.12-0.33-0.45
Other Non Cash Items
-0.10.69-0.4-0.350.170.280.36-0.390.02-0.190.73-0.11-0.840.11-0.1-0.44-0.82-0.7-0.650.25-0.17
Capital Expenditures
0.090.120.30.41-0.21-0.030.360.02-0.080.240.220.46-0.3-0.390.460.35-0.06-0.23-0.210.26-0.45
Net Income
0.05-0.850.9-0.040.19-0.75-0.390.020.27-0.09-0.770.340.37-0.61-0.340.350.44-0.15-0.210.010.3
End Period Cash Flow
0.7-0.310.320.10.01-0.450.02-0.080.270.13-0.110.140.21-0.22-0.20.150.050.020.00.040.73
Change To Liabilities
0.240.040.150.56-0.21-0.25-0.190.24-0.090.13-0.060.0-0.060.180.30.460.390.040.070.230.08
Change To Netincome
0.00.84-0.71-0.26-0.110.620.730.22-0.77-0.11-0.06-0.01-0.650.220.21-0.24-0.73-0.22-0.160.05-0.35
Sale Purchase Of Stock
0.34-0.430.440.07-0.33-0.1-0.110.460.340.140.0-0.010.32-0.810.00.690.21-0.01-0.070.06-0.21
Change To Inventory
0.26-0.770.410.36-0.16-0.28-0.84-0.30.370.21-0.06-0.650.32-0.32-0.070.380.670.730.67-0.230.23
Investments
-0.050.56-0.610.04-0.160.370.11-0.39-0.61-0.220.180.22-0.81-0.320.05-0.43-0.140.060.12-0.190.11
Net Borrowings
0.050.32-0.170.31-0.260.25-0.10.46-0.34-0.20.30.210.0-0.070.050.21-0.040.430.5-0.14-0.28
Cash And Cash Equivalents Changes
0.53-0.50.570.43-0.6-0.15-0.440.350.350.150.46-0.240.690.38-0.430.210.60.210.17-0.31-0.05
Cash Flows Other Operating
0.25-0.720.560.54-0.31-0.3-0.82-0.060.440.050.39-0.730.210.67-0.14-0.040.60.410.35-0.060.01
Change To Account Receivables
0.2-0.25-0.010.46-0.250.09-0.7-0.23-0.150.020.04-0.22-0.010.730.060.430.210.410.99-0.390.02
Change Receivables
0.18-0.16-0.070.46-0.250.12-0.65-0.21-0.210.00.07-0.16-0.070.670.120.50.170.350.99-0.390.01
Change To Operating Activities
-0.330.1-0.02-0.050.5-0.330.250.260.010.040.230.050.06-0.23-0.19-0.14-0.31-0.06-0.39-0.39-0.18
Issuance Of Capital Stock
0.47-0.290.22-0.020.06-0.45-0.17-0.450.30.730.08-0.35-0.210.230.11-0.28-0.050.010.020.01-0.18
Click cells to compare fundamentals

Regulus Therapeutics Account Relationship Matchups

High Positive Relationship

Change Receivables
+ 0.99
Change To Account Receivables
Net Income
+ 0.9
Free Cash Flow
Change To Netincome
+ 0.84
Stock Based Compensation
Change To Netincome
+ 0.73
Other Non Cash Items
Issuance Of Capital Stock
+ 0.73
End Period Cash Flow
Change To Account Receivables
+ 0.73
Change To Inventory

High Negative Relationship

Net Income
- 0.85
Stock Based Compensation
Change To Inventory
- 0.84
Other Non Cash Items
Cash Flows Other Operating
- 0.82
Other Non Cash Items
Free Cash Flow
- 0.82
Stock Based Compensation
Investments
- 0.81
Sale Purchase Of Stock
Change To Netincome
- 0.77
Net Income

Regulus Therapeutics cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash20.2M(3.0M)29.4M(36.2M)(461K)(438.0K)
Stock Based Compensation2.3M2.6M2.9M2.2M2.8M3.9M
Free Cash Flow(20.1M)(12.5M)(24.4M)(25.9M)(27.4M)(28.8M)
Change In Working Capital(6.6M)(41K)914K550K257K269.9K
Begin Period Cash Flow13.9M34.1M31.1M60.4M24.3M27.6M
Other Cashflows From Financing Activities3K5K26K(15.1M)15.1M15.9M
Depreciation931K467K459K122K227K215.7K
Other Non Cash Items2.1M154K46K(52K)(16K)(15.2K)
Capital Expenditures244K11K251K361K613K611.5K
Total Cash From Operating Activities(19.8M)(12.5M)(24.1M)(25.5M)(26.8M)(28.1M)
Net Income(18.6M)(15.7M)(27.8M)(28.3M)(30.0M)(31.5M)
Total Cash From Financing Activities39.9M9.5M53.7M4.5M11.8M23.3M
End Period Cash Flow34.1M31.1M60.4M24.3M23.8M28.1M
Change To Liabilities(2.9M)(1.8M)(250K)(110K)(126.5K)(132.8K)
Total Cashflows From Investing Activities74K(11K)(251K)(15.1M)(17.4M)(16.5M)
Change To Netincome2.6M2.8M2.3M2.1M1.9M1.8M
Sale Purchase Of Stock43.4M220K42.2M19.1M17.2M27.7M
Change To Inventory(606K)270.0610.0304.0349.6367.08
Investments74K(11K)(251K)(15.1M)20.0M21.0M
Net Borrowings(3.3M)(2.0M)(10M)(80K)(72K)(68.4K)
Cash And Cash Equivalents Changes(1.4M)416K20.2M(3.0M)(2.7M)(2.6M)
Cash Flows Other Operating1.7M2.3M(705K)1.2M1.3M1.4M
Change To Account Receivables347K(1.1M)638K503K578.5K607.4K
Other Cashflows From Investing Activities(16K)46.5M295K(11K)(12.7K)(12.0K)
Change Receivables1.3M347K(1.1M)638K733.7K770.4K
Change To Operating Activities(2.8M)(497K)357K660K594K623.7K
Issuance Of Capital Stock42.2M19.1M53.8M4.5M15.2M18.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY